SCHEMBL6433224

SCHEMBL6433224

O=S(=O)(c1ccc2c(Cl)cnc(Cl)c2c1)N1CCC[C@@H]1CO

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 8/20 0.75
PIK3CD O00329 1/20 0.45
PIK3CG P48736 1/20 0.45
HTR7 P34969 2/20 0.44
HTR1A P08908 1/20 0.44
DRD2 P14416 1/20 0.44
HTR1D P28221 1/20 0.44
HTR1B P28222 1/20 0.44
HTR1E P28566 1/20 0.44
ADRA1B P35368 1/20 0.44
DRD3 P35462 1/20 0.44
LOX P28300 1/20 0.44
BRD4 O60885 1/20 0.44
BRD2 P25440 1/20 0.44
TSHR P16473 1/20 0.43
RORC P51449 1/20 0.42
PSEN1 P49768 1/20 0.42
PSEN2 P49810 1/20 0.42
APH1B Q8WW43 1/20 0.42
NCSTN Q92542 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6977110 0.84 PLAU (0.71) PLAUPIK3CDPIK3CGHTR7HTR1A
SCHEMBL6434427 0.83 PLAU (0.74) PLAUTSHRRECQL
Hydrochloric Acid SCHEMBL7378437 0.83 PLAU (0.70) PLAUPIK3CDPIK3CGHTR7HTR1A
Hydrochloric Acid SCHEMBL6436421 0.83 PLAU (0.70) PLAUPIK3CDPIK3CGHTR7HTR1A
SCHEMBL7379081 0.80 PLAU (0.75) PLAUTSHRRECQL
SCHEMBL6436381 0.80 PLAU (0.75) PLAUTSHRRECQL
SCHEMBL6433727 0.78 PLAU (0.57) PLAUTSHRRECQL
SCHEMBL6437779 0.78 PLAU (0.57) PLAUTSHRRECQL
SCHEMBL6433050 0.77 PLAU (0.67) PLAUTSHR
SCHEMBL29859509 0.77 PLAU (0.56) PLAUPIK3CDPIK3CGHTR7HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050026836-A1 Composition for the treatment of damaged tissue DACK KEVIN NEIL (GB) 2005-02-03 US disclosed
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885PIK3CD 2649/4885PIK3CG 2433/4885
US-20050026836-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885PIK3CD 2649/4885PIK3CG 2433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.